JP6647395B2 - Tablets containing tosfloxacin tosylate - Google Patents
Tablets containing tosfloxacin tosylate Download PDFInfo
- Publication number
- JP6647395B2 JP6647395B2 JP2018514690A JP2018514690A JP6647395B2 JP 6647395 B2 JP6647395 B2 JP 6647395B2 JP 2018514690 A JP2018514690 A JP 2018514690A JP 2018514690 A JP2018514690 A JP 2018514690A JP 6647395 B2 JP6647395 B2 JP 6647395B2
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- powder
- sieve
- tableting
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 title claims description 27
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 55
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 54
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 43
- 229960005261 aspartic acid Drugs 0.000 claims description 42
- 239000011230 binding agent Substances 0.000 claims description 41
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 39
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 39
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 33
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 28
- 229960000913 crospovidone Drugs 0.000 claims description 28
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 28
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 28
- 229920000642 polymer Polymers 0.000 claims description 27
- 108010010803 Gelatin Proteins 0.000 claims description 24
- 229920000159 gelatin Polymers 0.000 claims description 24
- 235000019322 gelatine Nutrition 0.000 claims description 24
- 235000011852 gelatine desserts Nutrition 0.000 claims description 24
- 229920002554 vinyl polymer Polymers 0.000 claims description 23
- 229940024606 amino acid Drugs 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 230000002378 acidificating effect Effects 0.000 claims description 18
- 239000008273 gelatin Substances 0.000 claims description 17
- 239000007884 disintegrant Substances 0.000 claims description 15
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 14
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 14
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 14
- 229950008138 carmellose Drugs 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 229940083542 sodium Drugs 0.000 claims description 9
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 7
- 229920000881 Modified starch Polymers 0.000 claims description 6
- 235000015424 sodium Nutrition 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 229960005069 calcium Drugs 0.000 claims description 4
- 239000003826 tablet Substances 0.000 description 244
- 239000000843 powder Substances 0.000 description 131
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 68
- 235000012239 silicon dioxide Nutrition 0.000 description 57
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 53
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 45
- 238000004090 dissolution Methods 0.000 description 37
- 239000000203 mixture Substances 0.000 description 35
- 239000004386 Erythritol Substances 0.000 description 34
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 34
- 235000019414 erythritol Nutrition 0.000 description 34
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 34
- 229940009714 erythritol Drugs 0.000 description 34
- 235000019359 magnesium stearate Nutrition 0.000 description 34
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 32
- 239000004575 stone Substances 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- 239000007864 aqueous solution Substances 0.000 description 22
- 238000005469 granulation Methods 0.000 description 22
- 230000003179 granulation Effects 0.000 description 21
- 239000004376 Sucralose Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- 235000019408 sucralose Nutrition 0.000 description 20
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 238000007873 sieving Methods 0.000 description 18
- 239000008187 granular material Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 238000007922 dissolution test Methods 0.000 description 9
- 239000007941 film coated tablet Substances 0.000 description 9
- 229920000578 graft copolymer Polymers 0.000 description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000004570 mortar (masonry) Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- -1 hydroxypropyl Chemical class 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 239000001116 FEMA 4028 Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 239000008030 superplasticizer Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TURGQPDWYFJEDY-UHFFFAOYSA-N 1-hydroperoxypropane Chemical class CCCOO TURGQPDWYFJEDY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920003115 HPC-SL Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229920003125 hypromellose 2910 Polymers 0.000 description 1
- 229940031672 hypromellose 2910 Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010665 pine oil Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940072132 quinolone antibacterials Drugs 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- JAOZKJMVYIWLKU-UHFFFAOYSA-N sodium 7-hydroxy-8-[(4-sulfonaphthalen-1-yl)diazenyl]naphthalene-1,3-disulfonic acid Chemical compound C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)N=NC3=C(C=CC4=CC(=CC(=C43)S(=O)(=O)O)S(=O)(=O)O)O.[Na+] JAOZKJMVYIWLKU-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- UOZXOFPVRJVDGV-UHFFFAOYSA-N sodium;4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound [Na].OS(=O)(=O)CCCCOCCCCS(O)(=O)=O UOZXOFPVRJVDGV-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- SSULTCPIIYRGFQ-UHFFFAOYSA-N tosufloxacin tosylate hydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F SSULTCPIIYRGFQ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000008371 vanilla flavor Substances 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Description
本発明は、速溶出性を示し、かつ打錠障害を起こさず、製造性に優れたトスフロキサシントシル酸塩を含む錠剤に関する。 The present invention relates to a tablet containing tosfloxacin tosylate, which exhibits fast dissolution, does not cause tableting trouble, and is excellent in productivity.
トスフロキサシンは、グラム陽性菌をはじめグラム陰性菌、嫌気性菌に対し広範囲な抗菌スペクトルを有するニューキノロン系の抗菌薬である（特許文献１）。トスフロキサシンを含む固形製剤の処方・製法としては、トスフロキサシントシル酸塩水和物、炭素数２〜６の有機酸および一般的な医療用の担体とを混合して製剤化することが知られている（特許文献２）。また、トスフロキサシントシル酸塩、糖または糖アルコールおよび非イオン性水溶性セルロース誘導体またはポリビニルアルコールからなる粒状固形製剤が知られている（特許文献３）。さらに、トスフロキサシントシル酸塩を含む錠剤が市販されている。 Tosfloxacin is a new quinolone antibacterial agent having a broad antibacterial spectrum against gram-positive bacteria, gram-negative bacteria, and anaerobic bacteria (Patent Document 1). As a formulation and manufacturing method of a solid preparation containing tosfloxacin, it is known that tosfloxacin tosylate hydrate, an organic acid having 2 to 6 carbon atoms, and a general medical carrier are mixed to form a preparation ( Patent Document 2). A granular solid preparation comprising tosfloxacin tosylate, sugar or sugar alcohol, and a nonionic water-soluble cellulose derivative or polyvinyl alcohol is also known (Patent Document 3). Additionally, tablets containing tosfloxacin tosylate are commercially available.
小児用固形製剤として、たとえば、粒状固形製剤および錠剤が知られている。嚥下機能の未発達な乳幼児には、粒状固形製剤が好ましい。しかし、小学生のように嚥下機能も発達し、さらに味覚がはっきりしてくると、錠剤が好まれる傾向にある。
錠剤は、その大きさが服薬コンプライアンスに大きく影響する。大きすぎる場合は、小児が嚥下できず、服薬コンプライアンスが低下する。成人用錠剤は、錠剤径が7.5〜8.5mmと小児には大きいため、小児の服薬コンプライアンスの低下が懸念される。
トスフロキサシントシル酸塩を含む小児用製剤として、細粒剤が市販されているが、小児用錠剤は開発されていない。
市販されているトスフロキサシントシル酸塩を含む錠剤の5分後の溶出率は24％である。小児において安定した薬剤吸収を得るためには、細粒剤と同等の速溶出性を示す錠剤の開発が望まれている。
さらに、トスフロキサシントシル酸塩は金属付着性があり、そのものを打錠した場合、原薬が杵に固着するという深刻な打錠障害（スティッキング）が生じる。特に、小児用錠に必要な割線を有する錠剤の安定製造には課題があった。
本発明の課題は、速やかな溶出性を示し、スティッキングなどの打錠障害を起こさず、製造性に優れたトスフロキサシントシル酸塩を含む錠剤を提供することである。As pediatric solid preparations, for example, granular solid preparations and tablets are known. For infants with undeveloped swallowing functions, granular solid preparations are preferred. However, when the swallowing function is developed as in elementary school children and the taste becomes clearer, tablets tend to be preferred.
The size of a tablet has a great influence on the compliance of the tablet. If too large, children will not be able to swallow and compliance will be reduced. Adult tablets have a tablet size of 7.5 to 8.5 mm, which is large for children.
Fine granules are commercially available as pediatric formulations containing tosfloxacin tosylate, but pediatric tablets have not been developed.
The dissolution rate after 5 minutes of a commercially available tablet containing tosfloxacin tosylate is 24%. In order to obtain stable drug absorption in children, the development of tablets exhibiting the same rapid dissolution properties as fine granules is desired.
Further, tosfloxacin tosylate has metal adhesion, and when tableted itself, serious tableting trouble (sticking) occurs in which the drug substance sticks to the punch. In particular, there has been a problem in the stable production of tablets having a score line required for pediatric tablets.
An object of the present invention is to provide a tablet containing tosfloxacin tosylate, which exhibits rapid dissolution, does not cause tableting trouble such as sticking, and is excellent in productivity.
このような状況下、本発明者らは鋭意研究を行った結果、（１）トスフロキサシントシル酸塩、（２）結合剤、および、（３）酸性アミノ酸を含む錠剤が、速溶出性を示し、かつ打錠障害を起こさず、製造性に優れることを見出し、本発明を完成させた。
本発明は、以下を提供する。Under these circumstances, the present inventors have conducted intensive studies, and as a result, tablets containing (1) tosfloxacin tosylate, (2) a binder, and (3) an acidic amino acid show rapid dissolution, In addition, they found that tableting did not occur, and that they were excellent in manufacturability, and completed the present invention.
The present invention provides the following.
［１］ （１）トスフロキサシントシル酸塩、（２）結合剤、および、（３）酸性アミノ酸、を含む錠剤であって；結合剤が、水溶性ポリビニル系高分子およびゼラチン類から選ばれる一種または二種以上であり、結合剤の含有率が、錠剤質量に対して５％未満である、錠剤。
［２］ 酸性アミノ酸が、Ｌ−アスパラギン酸である、［１］に記載の錠剤。
［３］ 結合剤が、水溶性ポリビニル系高分子である、［１］または［２］に記載の錠剤。
［４］ 水溶性ポリビニル系高分子が、ポリビニルアルコールおよびポリビニルピロリドンから選ばれる一種または二種以上である、［１］〜［３］のいずれか一に記載の錠剤。
［５］ 水溶性ポリビニル系高分子が、ポリビニルアルコールである、［１］〜［３］のいずれか一に記載の錠剤。
［６］ 水溶性ポリビニル系高分子の含有率が、錠剤質量に対して０．０１〜４．５％である、［１］〜［５］のいずれか一に記載の錠剤。
［７］ さらに崩壊剤を含む、［１］〜［６］のいずれか一に記載の錠剤。
［８］ 崩壊剤が、カルメロース、カルメロースカルシウム、クロスカルメロースナトリウム、低置換度ヒドロキシプロピルセルロース、クロスポビドン、カルボキシメチルスターチナトリウムおよび部分α化デンプンから選ばれる一種または二種以上である、［７］に記載の錠剤。[1] A tablet comprising (1) tosfloxacin tosylate, (2) a binder, and (3) an acidic amino acid, wherein the binder is one selected from a water-soluble polyvinyl polymer and gelatins. Two or more tablets, wherein the content of the binder is less than 5% based on the tablet mass.
[2] The tablet according to [1], wherein the acidic amino acid is L-aspartic acid.
[3] The tablet according to [1] or [2], wherein the binder is a water-soluble polyvinyl polymer.
[4] The tablet according to any one of [1] to [3], wherein the water-soluble polyvinyl polymer is one or more selected from polyvinyl alcohol and polyvinylpyrrolidone.
[5] The tablet according to any one of [1] to [3], wherein the water-soluble polyvinyl polymer is polyvinyl alcohol.
[6] The tablet according to any one of [1] to [5], wherein the content of the water-soluble polyvinyl polymer is 0.01 to 4.5% based on the mass of the tablet.
[7] The tablet according to any one of [1] to [6], further comprising a disintegrant.
[8] The disintegrant is one or more selected from carmellose, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropylcellulose, crospovidone, sodium carboxymethyl starch and partially pregelatinized starch. ] The tablet described in the above.
本発明は、さらに以下を提供する。
［Ａ］ さらに流動化剤を含む、［１］〜［８］のいずれか一に記載の錠剤。
［Ｂ］ 流動化剤が、含水二酸化ケイ素または軽質無水ケイ酸である、［Ａ］に記載の錠剤。
［Ｃ］ 結合剤が、ゼラチン類である、［１］または［２］に記載の錠剤。
［Ｄ］ ゼラチン類が、アルカリ処理ゼラチンである、［Ｃ］に記載の錠剤。
［Ｅ］ ゼラチン類の含有率が、錠剤質量に対して０．１〜４％である、［Ｃ］または［Ｄ］に記載の錠剤。The present invention further provides the following.
[A] The tablet according to any one of [1] to [8], further comprising a fluidizing agent.
[B] The tablet according to [A], wherein the superplasticizer is hydrous silicon dioxide or light anhydrous silicic acid.
[C] The tablet according to [1] or [2], wherein the binder is a gelatin.
[D] The tablet according to [C], wherein the gelatin is an alkali-treated gelatin.
[E] The tablet according to [C] or [D], wherein the content of gelatins is 0.1 to 4% based on the mass of the tablet.
［Ｆ］ （１）トスフロキサシントシル酸塩、（２）結合剤、および、（３）酸性アミノ酸、を含む錠剤であって；結合剤が、水溶性ポリビニル系高分子であり；酸性アミノ酸が、Ｌ−アスパラギン酸であり；水溶性ポリビニル系高分子の含有率が、錠剤質量に対して０．０１〜４．５％である、［１］に記載の錠剤。
［Ｇ］ （１）トスフロキサシントシル酸塩、（２）結合剤、および、（３）酸性アミノ酸、を含む錠剤であって；結合剤が、ポリビニルアルコールであり；酸性アミノ酸が、Ｌ−アスパラギン酸であり；ポリビニルアルコールの含有率が、錠剤質量に対して０．１〜４％である、［１］に記載の錠剤。[F] A tablet comprising (1) tosfloxacin tosylate, (2) a binder, and (3) an acidic amino acid, wherein the binder is a water-soluble polyvinyl polymer; -Aspartic acid; the tablet according to [1], wherein the content of the water-soluble polyvinyl polymer is 0.01 to 4.5% based on the tablet mass.
[G] A tablet comprising (1) tosfloxacin tosylate, (2) a binder, and (3) an acidic amino acid; wherein the binder is polyvinyl alcohol; and the acidic amino acid is L-aspartic acid. Yes; The tablet according to [1], wherein the content of polyvinyl alcohol is 0.1 to 4% based on the tablet mass.
本発明の錠剤は、小児等が服用し易く、速溶出性を示し、スティッキングなどの打錠障害を起こさず、製造性に優れたトスフロキサシントシル酸塩を含む錠剤である。
本発明の錠剤は、用量調節のための割線を有する錠剤とすることもでき、小児等の服薬コンプライアンスの向上した小児用の抗菌剤として有用である。The tablet of the present invention is a tablet containing tosfloxacin tosylate which is easy to be taken by children and the like, exhibits rapid dissolution, does not cause tableting trouble such as sticking, and is excellent in productivity.
The tablet of the present invention can be a tablet having a score line for dose adjustment, and is useful as an antibacterial agent for children with improved compliance with children.
本発明について以下に詳述する。
本明細書中に使用される％は、特に断りのない限り、質量％を意味する。
本明細書中に使用される各成分の含有率は、各成分に該当する物質が複数存在する場合、特に断らない限り、各成分に該当する複数の物質の合計の含有率を意味する。The present invention is described in detail below.
% Used in the present specification means% by mass unless otherwise specified.
The content of each component used in the present specification means the total content of a plurality of substances corresponding to each component unless there is a plurality of substances corresponding to each component, unless otherwise specified.
本明細書中に使用される「溶出率」は、特に断りのない限り、第16改正日本薬局方の溶出試験法第2法（パドル法）に従って測定される溶出率を意味する。
本明細書中に使用される「速溶出性」とは、溶出試験開始5分後の溶出率が60％以上であることを意味する。「60％以上」の値は、トスフロキサシントシル酸塩小児用細粒剤から、溶出挙動の類似性の指標であるf2関数を用いて求めた。
さらに、溶出試験開始5分後の溶出率が73%以上であることが、より好ましい。As used herein, “dissolution rate” means a dissolution rate measured according to the dissolution test method 2 (paddle method) of the 16th revision of the Japanese Pharmacopoeia, unless otherwise specified.
"Fast dissolution" as used herein means that the dissolution rate 5 minutes after the start of the dissolution test is 60% or more. The value of “60% or more” was determined from tosfloxacin tosylate pediatric fine granules using the f2 function, which is an index of similarity in dissolution behavior.
Further, the dissolution rate 5 minutes after the start of the dissolution test is more preferably 73% or more.
＜錠剤＞
本発明の錠剤は、トスフロキサシントシル酸塩、結合剤および酸性アミノ酸を含む。
本発明の錠剤とは、素錠およびフィルムコーティング錠を意味する。
フィルムコーティング錠とは、素錠に高分子化合物などのコーティング剤で剤皮を施した錠剤を意味する。
錠剤としては、フィルムコーティング錠が好ましい。
本発明の錠剤は、円形錠の場合、錠剤径が5.0〜7.0mmであることが好ましい。
本発明の錠剤を投与する場合、投与量および投与回数は、患者の年齢、体重および症状に応じて適宜選択できるが、通常、薬効を発揮しうる量を１日、１回から数回に分割して投与すればよい。通常、トスフロキサシンとして、１日、30〜2000mgを１回から数回に分割して投与すればよい。<Tablets>
The tablet of the present invention contains tosfloxacin tosylate, a binder and an acidic amino acid.
The tablet of the present invention means an uncoated tablet and a film-coated tablet.
The film-coated tablet means a tablet obtained by coating an uncoated tablet with a coating agent such as a polymer compound.
As tablets, film-coated tablets are preferred.
In the case of a round tablet, the tablet of the present invention preferably has a tablet diameter of 5.0 to 7.0 mm.
When administering the tablet of the present invention, the dosage and the number of administrations can be appropriately selected according to the patient's age, body weight and symptoms, but usually, the amount capable of exerting the drug effect is divided from once to several times a day. Should be administered. Usually, 30 to 2000 mg of tosfloxacin may be administered once a day in several divided doses.
＜トスフロキサシントシル酸塩＞
本発明に使用されるトスフロキサシントシル酸塩は、たとえば、特公昭６３−０２０８２８号公報に記載の方法により製造することができる。
本発明に使用されるトスフロキサシントシル酸塩は、水和物、溶媒和物および種々の形状の結晶ならびに非晶質固体を包含する。
本発明に使用されるトスフロキサシントシル酸塩は、水和物であることが好ましい。
トスフロキサシントシル酸塩の含有率は、錠剤質量に対して70％以下であることが好ましく、40〜60％であることがより好ましい。<Tosfloxacin tosylate>
The tosfloxacin tosylate used in the present invention can be produced, for example, by the method described in JP-B-63-020828.
Tosfloxacin tosylate used in the present invention includes hydrates, solvates and various forms of crystalline and amorphous solids.
The tosfloxacin tosylate used in the present invention is preferably a hydrate.
The content of tosfloxacin tosylate is preferably 70% or less, more preferably 40 to 60%, based on the tablet mass.
＜結合剤＞
本発明に使用される結合剤としては、水溶性ポリビニル系高分子およびゼラチン類から選ばれる一種または二種以上が挙げられ、水溶性ポリビニル系高分子が好ましい。
結合剤の含有率は、5％未満であればよい。
水溶性ポリビニル系高分子としては、たとえば、ポリビニルアルコール、ポリビニルピロリドンおよびポリビニルアルコール・ポリエチレングリコール・グラフトコポリマーから選ばれる一種または二種以上が挙げられ、ポリビニルアルコールおよびポリビニルピロリドンが好ましく、ポリビニルアルコールがより好ましい。
ポリビニルアルコールとしては、完全けん化ポリビニルアルコールおよび部分けん化ポリビニルアルコールが挙げられ、部分けん化ポリビニルアルコールが好ましい。
水溶性ポリビニル系高分子の含有率は、錠剤質量に対して0.01〜4.5％が好ましく、0.05〜4％がより好ましく、0.1〜3％がさらに好ましい。<Binder>
Examples of the binder used in the present invention include one or more selected from water-soluble polyvinyl polymers and gelatins, and water-soluble polyvinyl polymers are preferable.
The content of the binder may be less than 5%.
Examples of the water-soluble polyvinyl polymer include one or more selected from polyvinyl alcohol, polyvinylpyrrolidone and polyvinyl alcohol / polyethylene glycol / graft copolymer, with polyvinyl alcohol and polyvinyl pyrrolidone being preferred, and polyvinyl alcohol being more preferred. .
Examples of the polyvinyl alcohol include completely saponified polyvinyl alcohol and partially saponified polyvinyl alcohol, and partially saponified polyvinyl alcohol is preferable.
The content of the water-soluble polyvinyl polymer is preferably from 0.01 to 4.5%, more preferably from 0.05 to 4%, even more preferably from 0.1 to 3%, based on the mass of the tablet.
ゼラチン類としては、アルカリ処理ゼラチンおよび酸処理ゼラチンから選ばれる一種または二種が挙げられ、アルカリ処理ゼラチンが好ましい。
ゼラチン類の含有率は、錠剤質量に対して0.1〜4％が好ましく、0.3〜4％がより好ましく、0.5〜2％がさらに好ましい。Examples of gelatins include one or two selected from alkali-treated gelatin and acid-treated gelatin, with alkali-treated gelatin being preferred.
The content of gelatins is preferably 0.1% to 4%, more preferably 0.3% to 4%, and still more preferably 0.5% to 2% with respect to the tablet mass.
＜酸性アミノ酸＞
本発明に使用される酸性アミノ酸とは、分子内に二つ以上のカルボキシル基を有するアミノ酸を意味する。
本発明に使用される酸性アミノ酸としては、たとえば、アスパラギン酸およびグルタミン酸から選ばれる一種または二種が挙げられる。好ましい酸性アミノ酸としては、アスパラギン酸が挙げられ、Ｌ−アスパラギン酸がより好ましい。
酸性アミノ酸の含有率は、錠剤質量に対して5〜50％が好ましく、5〜30％がより好ましく、10〜20％がさらに好ましい。<Acid amino acid>
The acidic amino acid used in the present invention means an amino acid having two or more carboxyl groups in a molecule.
Examples of the acidic amino acid used in the present invention include one or two selected from aspartic acid and glutamic acid. Preferred acidic amino acids include aspartic acid, and L-aspartic acid is more preferred.
The content of the acidic amino acid is preferably from 5 to 50%, more preferably from 5 to 30%, even more preferably from 10 to 20% based on the mass of the tablet.
＜崩壊剤＞
本発明の錠剤は、さらに崩壊剤を含むことが好ましい。
本発明に使用される崩壊剤としては、たとえば、カルメロース、カルメロースカルシウム、クロスカルメロースナトリウム、低置換度ヒドロキシプロピルセルロース、クロスポビドン、カルボキシメチルスターチナトリウムおよび部分α化デンプンなどから選ばれる一種または二種以上が挙げられる。
好ましい崩壊剤としては、カルメロース、カルメロースカルシウム、クロスカルメロースナトリウム、低置換度ヒドロキシプロピルセルロース、クロスポビドンおよびカルボキシメチルスターチナトリウムから選ばれる一種または二種以上が挙げられ、カルメロース、低置換度ヒドロキシプロピルセルロース、クロスポビドンおよびカルボキシメチルスターチナトリウムから選ばれる一種または二種以上がより好ましく、低置換度ヒドロキシプロピルセルロースおよびクロスポビドンを組み合せることが、さらに好ましい。
低置換度ヒドロキシプロピルセルロースとは、セルロースの低置換度ヒドロキシプロピルエーテルであり、本品を乾燥したものは定量するとき、ヒドロキシプロポキシ基(−ＯＣ3Ｈ6ＯＨ：75.09) 5.0〜16.0％を含む。
崩壊剤の含有率は、錠剤質量に対して5〜50％が好ましく、5〜30％がより好ましく、8〜15％がさらに好ましい。<Disintegrant>
The tablet of the present invention preferably further contains a disintegrant.
As the disintegrant used in the present invention, for example, one or two selected from carmellose, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropylcellulose, crospovidone, sodium carboxymethyl starch and partially pregelatinized starch, etc. Species or more.
Preferred disintegrants include one or more selected from carmellose, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropylcellulose, crospovidone and sodium carboxymethyl starch, and carmellose, low-substituted hydroxypropyl One or more selected from cellulose, crospovidone and sodium carboxymethyl starch are more preferred, and a combination of low-substituted hydroxypropylcellulose and crospovidone is further preferred.
The low-substituted hydroxypropyl cellulose, low-substituted hydroxypropyl ether of cellulose, when quantifying what this product was dried, hydroxypropoxy group (-OC 3 H 6 OH: 75.09 ) containing 5.0 to 16.0% .
The content of the disintegrant is preferably from 5 to 50%, more preferably from 5 to 30%, even more preferably from 8 to 15% based on the mass of the tablet.
＜流動化剤＞
本発明の錠剤は、さらに流動化剤を含むことが好ましい。
流動化剤としては、たとえば、合成ケイ酸アルミニウム、含水二酸化ケイ素および軽質無水ケイ酸などから選ばれる一種または二種以上が挙げられ、含水二酸化ケイ素および軽質無水ケイ酸から選ばれる一種または二種が好ましく、軽質無水ケイ酸がより好ましい。<Plasticizer>
The tablet of the present invention preferably further contains a fluidizing agent.
Examples of the fluidizing agent include one or two or more selected from synthetic aluminum silicate, hydrated silicon dioxide and light anhydrous silicic acid, and one or two selected from hydrated silicon dioxide and light anhydrous silicic acid. Preferably, light anhydrous silicic acid is more preferable.
＜添加物＞
本発明の錠剤には、本発明の効果を害さない範囲で、通常、薬剤に用いられる添加物を使用することができる。
添加物としては、賦形剤、滑沢剤、甘味剤、着色剤、着香剤、界面活性剤、可塑剤およびコーティング剤などが挙げられる。
賦形剤としては、たとえば、エリスリトール、マンニトール、キシリトールおよびソルビトールなどの糖アルコール類；白糖、粉糖、乳糖およびブドウ糖などの糖類；α−シクロデキストリン、β−シクロデキストリン、γ−シクロデキストリン、ヒドロキシプロピルβ−シクロデキストリンおよびスルホブチルエーテルβ−シクロデキストリンナトリウムなどのシクロデキストリン類；結晶セルロースおよび微結晶セルロースなどのセルロース類；トウモロコシデンプン、バレイショデンプンおよびα化デンプンなどのでんぷん類；マロン酸およびフマル酸などのジカルボン酸；グリコール酸、グルコン酸、酒石酸、リンゴ酸およびクエン酸などのオキシカルボン酸；ならびにアスコルビン酸などの炭素数２〜６の有機酸などから選ばれる一種または二種以上が挙げられる。好ましい賦形剤としては、糖アルコール類が挙げられ、エリスリトールがより好ましい。賦形剤の使用量は特に限定されず、剤型に応じた量を使用すればよい。<Additives>
In the tablet of the present invention, additives usually used in medicine can be used as long as the effects of the present invention are not impaired.
Additives include excipients, lubricants, sweeteners, colorants, flavors, surfactants, plasticizers, coatings, and the like.
Examples of the excipient include sugar alcohols such as erythritol, mannitol, xylitol and sorbitol; sugars such as sucrose, powdered sugar, lactose and glucose; α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxypropyl cyclodextrins such as β-cyclodextrin and sulfobutyl ether sodium β-cyclodextrin; celluloses such as crystalline cellulose and microcrystalline cellulose; starches such as corn starch, potato starch and pregelatinized starch; malonic acid and fumaric acid. Dicarboxylic acid; one selected from oxycarboxylic acids such as glycolic acid, gluconic acid, tartaric acid, malic acid and citric acid; and organic acids having 2 to 6 carbon atoms such as ascorbic acid Others include two or more thereof. Preferred excipients include sugar alcohols, with erythritol being more preferred. The amount of the excipient used is not particularly limited, and may be an amount according to the dosage form.
滑沢剤としては、たとえば、ステアリン酸、ステアリン酸マグネシウム、ステアリン酸カルシウム、フマル酸ステアリルナトリウム、タルクおよびショ糖脂肪酸エステルなどから選ばれる一種または二種以上が挙げられる。
甘味剤としては、たとえば、アスパルテーム、サッカリン、ステビア、スクラロース、ソーマチンおよびアセスルファムカリウムなどから選ばれる一種または二種以上が挙げられる。
着色剤としては、たとえば、二酸化チタン、三二酸化鉄、黄色三二酸化鉄、黒酸化鉄、食用赤色１０２号、食用黄色４号および食用黄色５号などから選ばれる一種または二種以上が挙げられる。
着香剤としては、たとえば、オレンジ油、レモン油、ハッカ油およびパインオイルなどの精油；オレンジエッセンスおよびペパーミントエッセンスなどのエッセンス；チェリーフレーバー、バニラフレーバーおよびフルーツフレーバーなどのフレーバー；アップルミクロン、バナナミクロン、ピーチミクロン、ストロベリーミクロンおよびオレンジミクロンなどの粉末香料；バニリン；ならびにエチルバニリンなどから選ばれる一種または二種以上が挙げられる。
界面活性剤としては、たとえば、ラウリル硫酸ナトリウム、スルホコハク酸ジオクチルナトリウム、ポリソルベートおよびポリオキシエチレン硬化ヒマシ油から選ばれる一種または二種以上が挙げられる。
可塑剤としては、たとえば、クエン酸トリエチル、フタル酸ジブチル、マクロゴール（ポリエチレングリコール）、トリアセチン、グリセロールモノカプリルカプレート、レシチンおよびプロピレングリコールなどから選ばれる一種または二種以上が挙げられる。Examples of the lubricant include one or more selected from stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, talc, and sucrose fatty acid ester.
Examples of the sweetener include one or more selected from aspartame, saccharin, stevia, sucralose, thaumatin, and acesulfame potassium.
Examples of the colorant include one or more selected from titanium dioxide, iron sesquioxide, yellow iron sesquioxide, black iron oxide, edible red 102, edible yellow 4 and edible yellow 5 and the like.
Flavoring agents include, for example, essential oils such as orange oil, lemon oil, peppermint oil and pine oil; essences such as orange essence and peppermint essence; flavors such as cherry flavor, vanilla flavor and fruit flavor; apple micron, banana micron, One or more selected from powdered flavors such as peach micron, strawberry micron and orange micron; vanillin; and ethyl vanillin.
Examples of the surfactant include one or more selected from sodium lauryl sulfate, dioctyl sodium sulfosuccinate, polysorbate, and polyoxyethylene hydrogenated castor oil.
Examples of the plasticizer include one or more selected from triethyl citrate, dibutyl phthalate, macrogol (polyethylene glycol), triacetin, glycerol monocaprylic plate, lecithin, propylene glycol, and the like.
コーティング剤としては、たとえば、高分子化合物、可塑剤、着色剤、滑沢剤および光沢化剤などから選ばれる一種または二種以上が挙げられる。
高分子化合物としては、たとえば、ヒプロメロース、ヒドロキシプロピルセルロース、ポリビニルアルコール、ポリビニルアルコール・アクリル酸・メタクリル酸メチル共重合体およびポリビニルアルコール・ポリエチレングリコール・グラフトコポリマーなどから選ばれる一種または二種以上が挙げられる。
コーティング剤として使用される滑沢剤としては、たとえば、タルクなどが挙げられる。
光沢化剤としては、たとえば、カルナウバロウ、サラシミツロウおよびミツロウなどから選ばれる一種または二種以上が挙げられる。
高分子化合物、可塑剤、着色剤、滑沢剤および光沢化剤の使用量は、特に限定されず、目的に応じて必要な量を適宜配合すればよい。
これらの添加物は、いずれか一種または二種以上を組み合わせて添加してよく、添加量も特に限定されず、剤型に応じた量を添加すればよい。Examples of the coating agent include one or more selected from a polymer compound, a plasticizer, a coloring agent, a lubricant, a glossing agent, and the like.
Examples of the polymer compound include one or more selected from hypromellose, hydroxypropyl cellulose, polyvinyl alcohol, polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer, polyvinyl alcohol / polyethylene glycol / graft copolymer, and the like. .
Examples of the lubricant used as a coating agent include talc.
Examples of the brightener include one or more selected from carnauba wax, beeswax and beeswax.
The amounts of the polymer compound, the plasticizer, the coloring agent, the lubricant, and the glossing agent are not particularly limited, and the necessary amounts may be appropriately blended according to the purpose.
These additives may be added alone or in combination of two or more, and the amount of addition is not particularly limited, and may be an amount according to the dosage form.
本発明の好ましい錠剤は、（１）トスフロキサシントシル酸塩、（２）結合剤、および、（３）酸性アミノ酸、を含む錠剤であって；結合剤が、水溶性ポリビニル系高分子であり；酸性アミノ酸が、Ｌ−アスパラギン酸であり；水溶性ポリビニル系高分子の含有率が、錠剤質量に対して0.01〜4.5％である、錠剤である。
好ましい水溶性ポリビニル系高分子は、前記と同様である。A preferred tablet of the present invention is a tablet comprising (1) tosfloxacin tosylate, (2) a binder, and (3) an acidic amino acid; wherein the binder is a water-soluble polyvinyl polymer; The tablet wherein the amino acid is L-aspartic acid; the content of the water-soluble polyvinyl polymer is 0.01 to 4.5% based on the tablet mass.
Preferred water-soluble polyvinyl polymers are the same as described above.
本発明のさらに好ましい錠剤は、（１）トスフロキサシントシル酸塩、（２）結合剤、および、（３）酸性アミノ酸、を含む錠剤であって；結合剤が、ポリビニルアルコールであり；酸性アミノ酸が、Ｌ−アスパラギン酸であり；ポリビニルアルコールの含有率が、錠剤質量に対して0.1〜4％である、錠剤である。
好ましいポリビニルアルコールは、前記と同様である。A further preferred tablet of the present invention is a tablet comprising (1) tosfloxacin tosylate, (2) a binder, and (3) an acidic amino acid; wherein the binder is polyvinyl alcohol; L-aspartic acid; tablets wherein the content of polyvinyl alcohol is 0.1-4% based on the tablet mass.
Preferred polyvinyl alcohols are the same as described above.
別の態様として、本発明の好ましい錠剤は、（１）トスフロキサシントシル酸塩、（２）結合剤、（３）酸性アミノ酸、（４）崩壊剤、および、（５）流動化剤、を含む錠剤であって；結合剤が、水溶性ポリビニル系高分子およびゼラチン類から選ばれる一種または二種以上であり；酸性アミノ酸が、Ｌ−アスパラギン酸であり；崩壊剤が、クロスポピドンおよび／またはカルボキシメチルスターチナトリウムを含む一種または二種以上であり；流動化剤が、含水二酸化ケイ素または軽質無水ケイ酸であり；結合剤の含有率が、錠剤質量に対して0.1〜3％である、錠剤である。 In another embodiment, a preferred tablet of the present invention is a tablet comprising (1) tosfloxacin tosylate, (2) a binder, (3) an acidic amino acid, (4) a disintegrant, and (5) a glidant. The binder is one or more selected from water-soluble polyvinyl polymers and gelatins; the acidic amino acid is L-aspartic acid; and the disintegrant is crospopidone and / or carboxymethyl One or more kinds including starch sodium; a fluidizing agent is hydrous silicon dioxide or light anhydrous silicic acid; a tablet having a binder content of 0.1 to 3% based on the tablet mass. .
＜製造方法＞
本発明の錠剤は、たとえば、トスフロキサシントシル酸塩に水溶性ポリビニル系高分子またはゼラチン類から選ばれる一種または二種以上の結合剤および酸性アミノ酸を添加し、さらに必要に応じて賦形剤、流動化剤、崩壊剤および／または甘味剤を添加し、湿式造粒法または乾式造粒法により造粒末を製造する。次いで、必要に応じて、賦形剤、流動化剤、崩壊剤および／または滑沢剤などを造粒末に加え、打錠用混合末とし、打錠することにより製造することができる。さらに常法により、フィルムコーティング錠を製造することができる。<Production method>
Tablets of the present invention, for example, tosfloxacin tosylate, one or more binders selected from water-soluble polyvinyl polymers or gelatins and acidic amino acids are added, if necessary, excipients, fluid An agent, a disintegrant and / or a sweetener are added, and the granulated powder is produced by a wet granulation method or a dry granulation method. Next, if necessary, an excipient, a fluidizing agent, a disintegrant, and / or a lubricant can be added to the granulated powder to prepare a mixed powder for tableting, and the tablet can be produced by tableting. Furthermore, a film-coated tablet can be produced by a conventional method.
本発明の造粒末の製造方法において好ましい造粒方法としては、湿式造粒法が挙げられる。
湿式造粒法としては、たとえば、流動層造粒法、転動流動造粒法、遠心転動造粒法、混合撹拌造粒法、高速混合撹拌造粒法、転動造粒法、湿式破砕造粒法および押出造粒法などが挙げられる。好ましい湿式造粒法としては、流動層造粒法、転動流動造粒法、高速混合撹拌造粒法および湿式破砕造粒法が挙げられ、流動層造粒法および転動流動造粒法がより好ましい。A preferred granulation method in the method for producing a granulated powder of the present invention includes a wet granulation method.
Examples of wet granulation include fluidized bed granulation, tumbling fluidized granulation, centrifugal tumbling granulation, mixing and stirring granulation, high-speed mixing and stirring granulation, tumbling granulation, and wet crushing. Granulation method and extrusion granulation method are mentioned. Preferred wet granulation methods include fluidized bed granulation method, tumbling fluidized granulation method, high-speed mixing stirring granulation method and wet crushing granulation method, and fluidized bed granulation method and tumbling fluidized granulation method are included. More preferred.
次に、本発明の錠剤の有用性を試験例、実施例および比較例で説明するが、本発明はこれらにより、限定されるものではない。
各試験例において各略号は、以下の意味を有する。
ＨＰＣ：ヒドロキシプロピルセルロース
ＨＰＭＣ：ヒドロキシプロピルメチルセルロース
Ｌ−ＨＰＣ：低置換度ヒドロキシプロピルセルロース
ＰＥＧ：ポリエチレングリコール
ＰＶＡ：ポリビニルアルコール
ＴＦＬＸ：トスフロキサシン
トスフロキサシントシル酸塩として、トスフロキサシントシル酸塩水和物を用いた。
カルボキシメチルスターチNa:カルボキシメチルスターチナトリウム
クロスカルメロースNa:クロスカルメロースナトリウム
ステアリン酸Mg:ステアリン酸マグネシウムNext, the usefulness of the tablet of the present invention will be described with reference to Test Examples, Examples and Comparative Examples, but the present invention is not limited thereto.
Each abbreviation in each test example has the following meaning.
HPC: hydroxypropylcellulose HPMC: hydroxypropylmethylcellulose L-HPC: low-substituted hydroxypropylcellulose PEG: polyethylene glycol PVA: polyvinyl alcohol TFLX: tosfloxacin Tosfloxacin tosylate hydrate was used as tosfloxacin tosylate.
Carboxymethyl starch Na: sodium carboxymethyl starch Croscarmellose Na: croscarmellose sodium Mg stearate: magnesium stearate
特に断らない限り、各成分は、以下のものを使用した。
α化デンプン：SWELSTAR WB-1（旭化成ケミカルズ）
Ｌ−アスパラギン酸：Ｌ−アスパラギン酸（協和発酵バイオ）
エリスリトール：エリスリトールT微粉（三菱化学フーズ）
カルボキシメチルスターチナトリウム：Primojel（DMV）
カルメロース：NS-300（五徳薬品）
含水二酸化ケイ素：カープレックス＃80（DSL.ジャパン）
クロスカルメロースナトリウム：キッコレート（旭化成ケミカルズ）
クロスポビドン：ポリプラスドンXL-10（ISP）
軽質無水ケイ酸：アエロジル200（日本アエロジル）
スクラロース：スクラロース（P）（三栄源エフ・エフ・アイ）
ステアリン酸マグネシウム：ステアリン酸マグネシウム 植物性（太平化学産業）
ゼラチン：ゼラチン#150（新田ゼラチン）
低置換度ヒドロキシプロピルセルロース：L-HPC LH-21（信越化学工業）
ヒドロキシプロピルセルロース：HPC-SL（日本曹達）
ヒドロキシプロピルメチルセルロース：TC-5E（信越化学工業）
ポリビニルアルコール（部分けん化物）：EG-05PW（日本合成化学工業）
ポリビニルアルコール・ポリエチレングリコール・グラフトコポリマー：コリコートIR（BASF）
ポリビニルピロリドン：K29/32（ISP）The following components were used unless otherwise specified.
Gelatinized starch: SWELSTAR WB-1 (Asahi Kasei Chemicals)
L-aspartic acid: L-aspartic acid (Kyowa Hakko Bio)
Erythritol: Erythritol T fine powder (Mitsubishi Chemical Foods)
Sodium carboxymethyl starch: Primojel (DMV)
Carmellose: NS-300 (Gotoku Pharmaceutical)
Hydrous silicon dioxide: Carplex # 80 (DSL. Japan)
Croscarmellose sodium: Kikkolate (Asahi Kasei Chemicals)
Crospovidone: polyplasdone XL-10 (ISP)
Light Silicic Anhydride: Aerosil 200 (Nippon Aerosil)
Sucralose: Sucralose (P) (San-Ei Gen FFI)
Magnesium stearate: Magnesium stearate vegetable (Taihei Chemical)
Gelatin: Gelatin # 150 (Nitta Gelatin)
Low substituted hydroxypropylcellulose: L-HPC LH-21 (Shin-Etsu Chemical Co., Ltd.)
Hydroxypropyl cellulose: HPC-SL (Nippon Soda)
Hydroxypropyl methylcellulose: TC-5E (Shin-Etsu Chemical Co., Ltd.)
Polyvinyl alcohol (partially saponified): EG-05PW (Nippon Synthetic Chemical Industry)
Polyvinyl alcohol / polyethylene glycol / graft copolymer: Koricoat IR (BASF)
Polyvinylpyrrolidone: K29 / 32 (ISP)
特に断らない限り、各装置は、以下のものを使用した。錠剤は、硬度が50〜70Nになるように打錠した。
打錠機：タブフレックスTAB10（岡田精工）
転動流動造粒乾燥機：マルチプレックスMP-01（パウレック）Unless otherwise specified, the following devices were used. Tablets were compressed to a hardness of 50-70N.
Tableting machine: Tabflex TAB10 (Okada Seiko)
Rolling fluidized granulation dryer: Multiplex MP-01 (Pourec)
試験例１
試験製剤として、実施例１〜２５および比較例１〜５の素錠を用いた。
（１）製剤の溶出試験
溶出性の基準値は、速溶出性の小児用細粒剤と類似の溶出性となるような、溶出試験開始5分後の溶出率を、溶出挙動の類似性の指標であるf2関数から求め、溶出試験開始5分後の溶出率≧60％を基準として設定した。
溶出試験は、第16改正日本薬局方の溶出試験法第2法（パドル法）によって行った。各試験製剤1錠を、水900mLに添加し、毎分50回転で撹拌した。溶出試験開始5分後に自動サンプリング装置により溶出液を採取し、孔径35μmのフィルターでろ過した。紫外可視吸光度測定法＜日本薬局方一般試験法2.24＞に従い、トスフロキサシントシル酸塩の濃度を測定した。Test example 1
Uncoated tablets of Examples 1 to 25 and Comparative Examples 1 to 5 were used as test preparations.
(1) Dissolution test of drug product The standard value of dissolution is determined by the dissolution rate 5 minutes after the start of the dissolution test so that the dissolution is similar to that of fast-dissolving pediatric fine granules. It was determined from the f2 function as an index, and was set based on a dissolution rate ≧ 60% 5 minutes after the start of the dissolution test.
The dissolution test was performed according to the dissolution test method 2 (paddle method) of the 16th revised Japanese Pharmacopoeia. One tablet of each test preparation was added to 900 mL of water and stirred at 50 revolutions per minute. Five minutes after the start of the dissolution test, the eluate was collected by an automatic sampling device, and filtered with a filter having a pore size of 35 μm. The concentration of tosfloxacin tosylate was measured according to the UV-visible absorbance measurement method <Japanese Pharmacopoeia General Test Method 2.24>.
（２）製剤の打錠性
打錠時のスティッキングの有無を評価した。
素錠の割線および刻印面の肉眼観察により、スティッキングの有無を評価した。
結果を以下に示す。(2) Tableting properties of the formulation The presence or absence of sticking during tableting was evaluated.
The presence or absence of sticking was evaluated by visual observation of the score line and the engraved surface of the uncoated tablet.
The results are shown below.
表１に結合剤の種類を変えた錠剤の処方、５分後溶出率およびスティッキングの有無を示す。
結合剤として水溶性ポリビニル系高分子である、ポリビニルアルコール、ポリビニルピロリドンもしくはポリビニルアルコール・ポリエチレングリコール・グラフトコポリマー（PVA・PEGグラフトコポリマー）またはゼラチンを含む実施例１〜４の錠剤は、５分後溶出率が75〜82％と速溶出性を示し、かつスティッキングの無い、割線および刻印が鮮明な錠剤であった。
一方、比較例１および２に示すように、結合剤としてヒドロキシプロピルセルロースまたはヒドロキシプロピルメチルセルロースを含む比較例１および２の錠剤は、５分後溶出率がそれぞれ82％および80％と速溶出性を示したが、スティッキングの発生により割線および刻印が不鮮明な錠剤であった。また、結合剤としてα化デンプンを含む比較例３の錠剤は、５分後溶出率が55％と速溶出性を示さず、かつスティッキングの発生により割線および刻印が不鮮明な素錠であった。結合剤として水溶性ポリビニル系高分子を含む錠剤は溶出性および製造性に優れたものであった。Table 1 shows the formulations of tablets with different kinds of binders, the dissolution rate after 5 minutes, and the presence or absence of sticking.
Tablets of Examples 1 to 4 containing polyvinyl alcohol, polyvinylpyrrolidone or polyvinyl alcohol / polyethylene glycol / graft copolymer (PVA / PEG graft copolymer) or gelatin, which are water-soluble polyvinyl polymers as a binder, elute after 5 minutes. The tablet showed a fast dissolution rate of 75 to 82% and had no sticking, and had clear score lines and marks.
On the other hand, as shown in Comparative Examples 1 and 2, the tablets of Comparative Examples 1 and 2 containing hydroxypropylcellulose or hydroxypropylmethylcellulose as binders showed a fast dissolution rate of 82% and 80% after 5 minutes, respectively. As shown, due to the occurrence of sticking, the tablet was not sharply scored and imprinted. In addition, the tablet of Comparative Example 3 containing pregelatinized starch as a binder did not show fast dissolution at a dissolution rate of 55% after 5 minutes, and had unclear score lines and marks due to sticking. Tablets containing a water-soluble polyvinyl polymer as a binder were excellent in dissolution and productivity.
表２、３および４に、使用する結合剤の量を変えた錠剤の処方、５分後溶出率およびスティッキングの有無を示す。
結合剤としてポリビニルアルコールを含む実施例５〜１３の錠剤は、結合剤の量が0.1〜4％に変化しても、５分後溶出率は63〜84％と速溶出性を示し、かつスティッキングが無く、割線および刻印が鮮明な錠剤であった。通常、打錠用顆粒を製造する際、結合剤は3％前後添加するが、ポリビニルアルコールの場合、非常に少ない添加量でも速溶出性および製造性において優れた効果がみられた。
なお、結合剤を添加しなかった比較例５の錠剤は、５分後溶出率が82％と速溶出性を示したが、スティッキングの発生により割線および刻印が不鮮明な錠剤しか得られなかった。
また、結合剤としてポリビニルピロリドンを含む実施例２および１４の錠剤ならびに結合剤としてポリビニルアルコール・ポリエチレングリコール・グラフトコポリマー（PVA・PEGグラフトコポリマー）を含む実施例３および１５の錠剤は、共に結合剤の量が1％および2％に変化しても速溶出性を示し、かつスティッキングが無く、割線および刻印が鮮明な錠剤であった。Tables 2, 3 and 4 show the formulations of tablets with varying amounts of binder used, the dissolution rate after 5 minutes and the presence or absence of sticking.
The tablets of Examples 5 to 13 containing polyvinyl alcohol as the binder show a quick dissolution of 63 to 84% after 5 minutes even when the amount of the binder changes to 0.1 to 4%, and sticking. There was no tablet, and the score and the marking were clear. Normally, when manufacturing granules for tableting, a binder is added at about 3%, but in the case of polyvinyl alcohol, excellent effects in quick dissolution and productivity were observed even with a very small amount of addition.
In addition, the tablet of Comparative Example 5 to which no binder was added showed a quick dissolution rate of 82% after 5 minutes, but only a tablet with unclear score and imprint due to occurrence of sticking was obtained.
The tablets of Examples 2 and 14 containing polyvinylpyrrolidone as a binder and the tablets of Examples 3 and 15 containing polyvinyl alcohol / polyethylene glycol / graft copolymer (PVA / PEG graft copolymer) as a binder were both Even when the amount was changed to 1% or 2%, the tablet showed fast dissolution, was free from sticking, and had a clear score and marking.
表５に結合剤として使用するゼラチンの量を変えた錠剤の処方、５分後溶出率およびスティッキングの有無を示す。
ゼラチンの量が0.5〜2％である実施例４、１６および１７の錠剤は、５分後溶出率が75〜79％と速溶出性を示し、かつスティッキングが無く、割線および刻印が鮮明な錠剤であった。Table 5 shows the formulation of the tablet in which the amount of gelatin used as the binder was changed, the dissolution rate after 5 minutes, and the presence or absence of sticking.
The tablets of Examples 4, 16 and 17 in which the amount of gelatin is 0.5 to 2% have a dissolution rate of 75 to 79% after 5 minutes, exhibit fast dissolution, have no sticking, and have clear score lines and engraving. Met.
表６に結合剤としてポリビニルアルコールを使用し、崩壊剤を種々変えた錠剤の処方、５分後溶出率およびスティッキングの有無を示す。
実施例１８〜２３の錠剤は、５分後溶出率が62〜80％と速溶出性を示し、かつスティッキングが無く、割線および刻印が鮮明な錠剤であった。本発明の錠剤は崩壊剤の種類および組み合わせによらず、速溶出性と製造性に優れたものであった。Table 6 shows the formulations of tablets using polyvinyl alcohol as a binder and variously changing disintegrants, the dissolution rate after 5 minutes, and the presence or absence of sticking.
The tablets of Examples 18 to 23 exhibited fast dissolution at a dissolution rate of 62 to 80% after 5 minutes, had no sticking, and had clear score lines and marks. The tablet of the present invention was excellent in quick dissolution and productivity regardless of the type and combination of disintegrants.
表７に結合剤としてポリビニルアルコールを使用し、流動化剤の種類または量を変えた錠剤の処方、５分後溶出率およびスティッキングの有無を示す。
流動化剤を含まない実施例２４の錠剤および流動化剤として含水二酸化ケイ素を含む実施例２５の錠剤は、５分後溶出率が62％および74％と速溶出性を示し、かつスティッキングが無く、割線および刻印が鮮明な素錠であった。
流動化剤を含む製剤は、含まない製剤よりも優れた速溶出性を示したことから、流動化剤を含むことがより好ましい。Table 7 shows the tablet formulations in which polyvinyl alcohol was used as the binder and the type or amount of the fluidizing agent was changed, the dissolution rate after 5 minutes, and the presence or absence of sticking.
The tablet of Example 24 containing no superplasticizer and the tablet of Example 25 containing hydrous silicon dioxide as the superplasticizer showed fast dissolution of 62% and 74% after 5 minutes, and showed no sticking. , The score line and the stamp were clear uncoated tablets.
It is more preferable that the formulation containing a fluidizing agent contains a fluidizing agent, since the formulation containing the fluidizing agent showed faster dissolution than the formulation containing no fluidizing agent.
実施例１
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール33.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ポリビニルアルコール（部分けん化物）水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 1
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 33.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed and measured. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 1% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed and granulated, and dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例２
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール33.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ポリビニルピロリドン水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 2
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 33.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed and measured. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 1% aqueous solution of polyvinylpyrrolidone was sprayed and granulated, and dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例３
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール33.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ポリビニルアルコール・ポリエチレングリコール・グラフトコポリマー水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 3
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 33.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed and measured. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 1% aqueous solution of polyvinyl alcohol / polyethylene glycol / graft copolymer was sprayed to granulate, dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例４
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール33.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ゼラチン水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 4
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 33.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed and measured. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 1% gelatin aqueous solution was sprayed to granulate, dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例５
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール34.8g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、0.1％ポリビニルアルコール（部分けん化物）水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 5
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 34.8 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed out. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 0.1% aqueous solution of polyvinyl alcohol (partially saponified product) was sprayed to granulate, dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例６
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール34.6g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、0.2％ポリビニルアルコール（部分けん化物）水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 6
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 34.6 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 0.2% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed and granulated, and dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例７
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール34.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、0.5％ポリビニルアルコール（部分けん化物）水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 7
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 34.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 0.5% aqueous solution of polyvinyl alcohol (partially saponified product) was sprayed to granulate, dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例８
トスフロキサシントシル酸塩水和物7.50g、Ｌ−アスパラギン酸2.25g、エリスリトール2.50g、含水二酸化ケイ素0.30g、低置換度ヒドロキシプロピルセルロース1.50gおよびポリビニルアルコール（部分けん化物）0.29gを秤取し、目開き500μmの篩で篩過後、混合した。その末を乳鉢に入れ、水を添加しながら造粒し、目開き850μmの篩で整粒後乾燥し、さらに、目開き500μmの篩で整粒して造粒末を得た。この造粒末に2％相当量のステアリン酸マグネシウムを目開き500μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり117mgの割線および刻印を有する円形の素錠を得た。Example 8
7.50 g of tosfloxacin tosylate hydrate, 2.25 g of L-aspartic acid, 2.50 g of erythritol, 0.30 g of hydrous silicon dioxide, 1.50 g of low-substituted hydroxypropylcellulose and 0.29 g of polyvinyl alcohol (partially saponified product) were weighed, The mixture was sieved with a 500 μm sieve and then mixed. The powder was placed in a mortar, granulated while adding water, sized with a sieve having an opening of 850 μm, dried, and further sized with a sieve having an opening of 500 μm to obtain a granulated powder. To this granulated powder, 2% equivalent of magnesium stearate was added through a sieve with openings of 500 μm and mixed to obtain a tableted powder. The tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go-stone surface to obtain a round plain tablet having a score of 117 mg per tablet and engraving.
実施例９
トスフロキサシントシル酸塩水和物7.50g、Ｌ−アスパラギン酸2.25g、エリスリトール2.50g、含水二酸化ケイ素0.30g、低置換度ヒドロキシプロピルセルロース1.50gおよびポリビニルアルコール（部分けん化物）0.44gを秤取し、目開き500μmの篩で篩過後、混合した。その末を乳鉢に入れ、水を添加しながら造粒し、目開き850μmの篩で整粒後乾燥し、さらに、目開き500μmの篩で整粒して造粒末を得た。この造粒末に2％相当量のステアリン酸マグネシウムを目開き500μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり118mgの割線および刻印を有する円形の素錠を得た。Example 9
7.50 g of tosfloxacin tosylate hydrate, 2.25 g of L-aspartic acid, 2.50 g of erythritol, 0.30 g of hydrous silicon dioxide, 1.50 g of low-substituted hydroxypropylcellulose, and 0.44 g of polyvinyl alcohol (partially saponified product) were weighed and measured. The mixture was sieved with a 500 μm sieve and then mixed. The powder was placed in a mortar, granulated while adding water, sized with a sieve having an opening of 850 μm, dried, and further sized with a sieve having an opening of 500 μm to obtain a granulated powder. To this granulated powder, 2% equivalent of magnesium stearate was added through a sieve with openings of 500 μm and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go-stone surface to obtain a round plain tablet having a score of 118 mg per tablet and a stamp.
実施例１０
トスフロキサシントシル酸塩水和物7.50g、Ｌ−アスパラギン酸2.25g、エリスリトール2.50g、含水二酸化ケイ素0.30g、低置換度ヒドロキシプロピルセルロース1.50gおよびポリビニルアルコール（部分けん化物）0.59gを秤取し、目開き500μmの篩で篩過後、混合した。その末を乳鉢に入れ、水を添加しながら造粒し、目開き850μmの篩で整粒後乾燥し、さらに、目開き500μmの篩で整粒して造粒末を得た。この造粒末に2％相当量のステアリン酸マグネシウムを目開き500μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 10
7.50 g of tosfloxacin tosylate hydrate, 2.25 g of L-aspartic acid, 2.50 g of erythritol, 0.30 g of hydrous silicon dioxide, 1.50 g of low-substituted hydroxypropylcellulose, and 0.59 g of polyvinyl alcohol (partially saponified product) The mixture was sieved with a 500 μm sieve and mixed. The powder was placed in a mortar, granulated while adding water, sized with a sieve having an opening of 850 μm, dried, and further sized with a sieve having an opening of 500 μm to obtain a granulated powder. To this granulated powder, 2% equivalent of magnesium stearate was added through a sieve with openings of 500 μm and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例１１
トスフロキサシントシル酸塩水和物7.50g、Ｌ−アスパラギン酸2.25g、エリスリトール2.33g、軽質無水ケイ酸0.6g、低置換度ヒドロキシプロピルセルロース0.9g、クロスポビドン0.6g、ポリビニルアルコール（部分けん化物）0.3gおよびスクラロース0.075gを秤取し、目開き500μmの篩で篩過後、混合した。その末を乳鉢に入れ、水を添加しながら造粒し、目開き850μmの篩で整粒後乾燥し、さらに、目開き500μmの篩で整粒して造粒末を得た。この造粒末に素錠質量に対して0.5%相当量の軽質無水ケイ酸および2.5％相当量のステアリン酸マグネシウムを目開き500μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 11
Tosfloxacin tosylate hydrate 7.50 g, L-aspartic acid 2.25 g, erythritol 2.33 g, light anhydrous silicic acid 0.6 g, low-substituted hydroxypropylcellulose 0.9 g, crospovidone 0.6 g, polyvinyl alcohol (partially saponified product) 0.3 g Then, 0.075 g of sucralose was weighed, sieved with a sieve having an opening of 500 μm, and then mixed. The powder was placed in a mortar, granulated while adding water, sized with a sieve having an opening of 850 μm, dried, and further sized with a sieve having an opening of 500 μm to obtain a granulated powder. To the granulated powder, 0.5% of light anhydrous silicic acid and 2.5% of magnesium stearate corresponding to the mass of the uncoated tablet were added through a sieve with openings of 500 μm, and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例１２
トスフロキサシントシル酸塩水和物7.50g、Ｌ−アスパラギン酸2.25g、エリスリトール2.18g、軽質無水ケイ酸0.6g、低置換度ヒドロキシプロピルセルロース0.9g、クロスポビドン0.6g、ポリビニルアルコール（部分けん化物）0.45gおよびスクラロース0.075gを秤取し、目開き500μmの篩で篩過後、混合した。その末を乳鉢に入れ、水を添加しながら造粒し、目開き850μmの篩で整粒後乾燥し、さらに、目開き500μmの篩で整粒して造粒末を得た。この造粒末に素錠質量に対して0.5%相当量の軽質無水ケイ酸および2.5％相当量のステアリン酸マグネシウムを目開き500μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 12
Tosfloxacin tosylate hydrate 7.50 g, L-aspartic acid 2.25 g, erythritol 2.18 g, light anhydrous silicic acid 0.6 g, low-substituted hydroxypropylcellulose 0.9 g, crospovidone 0.6 g, polyvinyl alcohol (partially saponified product) 0.45 g Then, 0.075 g of sucralose was weighed, sieved with a sieve having an opening of 500 μm, and then mixed. The powder was placed in a mortar, granulated while adding water, sized with a sieve having an opening of 850 μm, dried, and further sized with a sieve having an opening of 500 μm to obtain a granulated powder. To the granulated powder, 0.5% of light anhydrous silicic acid and 2.5% of magnesium stearate corresponding to the mass of the uncoated tablet were added through a sieve with openings of 500 μm, and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例１３
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール27.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、4％ポリビニルアルコール（部分けん化物）水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 13
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 27.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed, After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 4% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed and granulated, and dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例１４
トスフロキサシントシル酸塩水和物7.50g、Ｌ−アスパラギン酸2.25g、エリスリトール2.50g、含水二酸化ケイ素0.30g、低置換度ヒドロキシプロピルセルロース1.50g、ポリビニルピロリドン0.29gを秤取し、目開き500μmの篩で篩過後、混合した。その末を乳鉢に入れ、水を添加しながら造粒し、目開き850μmの篩で整粒後乾燥し、さらに、目開き500μmの篩で整粒して造粒末を得た。この造粒末に2％相当量のステアリン酸マグネシウムを目開き500μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり117mgの割線および刻印を有する円形の素錠を得た。Example 14
7.50 g of tosfloxacin tosylate hydrate, 2.25 g of L-aspartic acid, 2.50 g of erythritol, 0.30 g of hydrated silicon dioxide, 1.50 g of low-substituted hydroxypropylcellulose, and 0.29 g of polyvinylpyrrolidone were weighed out and sieved with a sieve having an opening of 500 μm. After sieving, they were mixed. The powder was placed in a mortar, granulated while adding water, sized with a sieve having an opening of 850 μm, dried, and further sized with a sieve having an opening of 500 μm to obtain a granulated powder. To this granulated powder, 2% equivalent of magnesium stearate was added through a sieve with openings of 500 μm and mixed to obtain a tableted powder. The tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go-stone surface to obtain a round plain tablet having a score of 117 mg per tablet and engraving.
実施例１５
トスフロキサシントシル酸塩水和物7.50g、Ｌ−アスパラギン酸2.25g、エリスリトール2.50g、含水二酸化ケイ素0.30g、低置換度ヒドロキシプロピルセルロース1.50g、ポリビニルアルコール・ポリエチレングリコール・グラフトコポリマー0.29gを秤取し、目開き500μmの篩で篩過後、混合した。その末を乳鉢に入れ、水を添加しながら造粒し、目開き850μmの篩で整粒後乾燥し、さらに、目開き500μmの篩で整粒して造粒末を得た。この造粒末に2％相当量のステアリン酸マグネシウムを目開き500μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり117mgの割線および刻印を有する円形の素錠を得た。Example 15
7.50 g of tosfloxacin tosylate hydrate, 2.25 g of L-aspartic acid, 2.50 g of erythritol, 0.30 g of hydrous silicon dioxide, 1.50 g of low-substituted hydroxypropylcellulose, and 0.29 g of polyvinyl alcohol / polyethylene glycol / graft copolymer were weighed out. After sieving through a sieve with openings of 500 μm, they were mixed. The powder was placed in a mortar, granulated while adding water, sized with a sieve having an opening of 850 μm, dried, and further sized with a sieve having an opening of 500 μm to obtain a granulated powder. To this granulated powder, 2% equivalent of magnesium stearate was added through a sieve with openings of 500 μm and mixed to obtain a tableted powder. The tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go-stone surface to obtain a round plain tablet having a score of 117 mg per tablet and engraving.
実施例１６
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール34.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、0.5％ゼラチン水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 16
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 34.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 0.5% gelatin aqueous solution was sprayed to granulate, dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例１７
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール31.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、2％ゼラチン水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 17
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 31.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 2% gelatin aqueous solution was sprayed and granulated, and dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例１８
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール32.0g、軽質無水ケイ酸10.0g、カルメロース10.0gおよび低置換度ヒドロキシプロピルセルロース10.0gを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、0.67％ポリビニルアルコール（部分けん化物）水溶液300.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して3.0％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 18
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 32.0 g of erythritol, 10.0 g of light anhydrous silicic acid, 10.0 g of carmellose and 10.0 g of low-substituted hydroxypropylcellulose were weighed out and sieved with a sieve having an opening of 500 μm. After sieving, the mixture was charged into a tumbling fluidized-granulation dryer and mixed. Thereafter, 300.0 g of a 0.67% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed to granulate, dried and sized to obtain a granulated powder. Magnesium stearate equivalent to 3.0% of the mass of the uncoated tablet was added to the granulated powder through a sieve with openings of 180 μm, and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例１９
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール32.0g、軽質無水ケイ酸10.0g、カルメロース10.0gおよびクロスポビドン10.0gを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、0.67％ポリビニルアルコール（部分けん化物）水溶液300.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して3.0％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 19
After weighing 100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 32.0 g of erythritol, 10.0 g of light anhydrous silicic acid, 10.0 g of carmellose and 10.0 g of crospovidone, the mixture was sieved with a sieve having an opening of 500 μm. The mixture was charged into a dynamic fluidized granulation dryer and mixed. Thereafter, 300.0 g of a 0.67% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed to granulate, dried and sized to obtain a granulated powder. Magnesium stearate equivalent to 3.0% of the mass of the uncoated tablet was added to the granulated powder through a sieve with openings of 180 μm, and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例２０
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール32.0g、軽質無水ケイ酸10.0g、低置換度ヒドロキシプロピルセルロース10.0gおよびクロスポビドン10.0gを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、0.67％ポリビニルアルコール（部分けん化物）水溶液300.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して3.0％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 20
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 32.0 g of erythritol, 10.0 g of light anhydrous silicic acid, 10.0 g of low-substituted hydroxypropylcellulose and 10.0 g of crospovidone were weighed, and a sieve having an aperture of 500 μm was weighed. , And charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 300.0 g of a 0.67% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed to granulate, dried and sized to obtain a granulated powder. Magnesium stearate equivalent to 3.0% of the mass of the uncoated tablet was added to the granulated powder through a sieve with openings of 180 μm, and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例２１
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール32.0g、軽質無水ケイ酸10.0gおよび低置換度ヒドロキシプロピルセルロース20.0gを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ポリビニルアルコール（部分けん化物）水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して3.0％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 21
After weighing 100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 32.0 g of erythritol, 10.0 g of light anhydrous silicic acid and 20.0 g of low-substituted hydroxypropylcellulose, the mixture was sieved with a sieve having an opening of 500 μm. The mixture was charged into a dynamic fluidized granulation dryer and mixed. Thereafter, 200.0 g of a 1% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed and granulated, and dried and sized to obtain a granulated powder. Magnesium stearate equivalent to 3.0% of the mass of the uncoated tablet was added to the granulated powder through a sieve with openings of 180 μm, and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例２２
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール32.0g、軽質無水ケイ酸10.0gおよびクロスカルメロースナトリウム20.0gを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ポリビニルアルコール（部分けん化物）水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して3.0％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 22
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 32.0 g of erythritol, 10.0 g of light anhydrous silicic acid and 20.0 g of croscarmellose sodium were weighed, sieved with a sieve having an opening of 500 μm, and then tumbled. It was charged in a granulation dryer and mixed. Thereafter, 200.0 g of a 1% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed and granulated, and dried and sized to obtain a granulated powder. Magnesium stearate equivalent to 3.0% of the mass of the uncoated tablet was added to the granulated powder through a sieve with openings of 180 μm, and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例２３
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール32.0g、軽質無水ケイ酸10.0gおよびカルボキシメチルスターチナトリウム20.0gを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ポリビニルアルコール（部分けん化物）水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して3.0％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 23
After weighing 100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 32.0 g of erythritol, 10.0 g of light anhydrous silicic acid and 20.0 g of sodium carboxymethyl starch, the mixture was sieved with a sieve having an opening of 500 μm and then tumbled. It was charged in a granulation dryer and mixed. Thereafter, 200.0 g of a 1% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed and granulated, and dried and sized to obtain a granulated powder. Magnesium stearate equivalent to 3.0% of the mass of the uncoated tablet was added to the granulated powder through a sieve with openings of 180 μm, and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例２４
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール43.3g、カルメロース10.0gおよびクロスポビドン10.0gを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ポリビニルアルコール（部分けん化物）水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して2.0％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 24
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 43.3 g of erythritol, 10.0 g of carmellose and 10.0 g of crospovidone were weighed out, sieved with a sieve having an opening of 500 μm, and then tumbled into a fluidized-bed granulating dryer. Charged and mixed. Thereafter, 200.0 g of a 1% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed and granulated, and dried and sized to obtain a granulated powder. To this granulated powder, magnesium stearate in an amount equivalent to 2.0% based on the mass of the uncoated tablet was added through a sieve having openings of 180 μm, and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例２５
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール33.3g、含水二酸化ケイ素10.0g、カルメロース10.0gおよびクロスポビドン10.0gを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ポリビニルアルコール（部分けん化物）水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して2.0％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Example 25
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 33.3 g of erythritol, 10.0 g of hydrous silicon dioxide, 10.0 g of carmellose and 10.0 g of crospovidone were weighed, sieved with a sieve having an opening of 500 μm, and then tumbled. The mixture was charged into a fluidized granulation dryer and mixed. Thereafter, 200.0 g of a 1% aqueous solution of polyvinyl alcohol (partially saponified) was sprayed and granulated, and dried and sized to obtain a granulated powder. To this granulated powder, magnesium stearate in an amount equivalent to 2.0% based on the mass of the uncoated tablet was added through a sieve having openings of 180 μm, and mixed to obtain a tableted powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
実施例２６
実施例５の素錠に、錠剤コーティング機（DRC-200、パウレック製）にて、コーティング剤（OPADRY 00F440000、日本カラコン合同会社：ヒプロメロース2910 71.500％、マクロゴール6000 14.166％、タルク7.167％、酸化チタン7.067％、三二酸化鉄 0.100％を水に分散したもの）を1錠あたり4mgの割合でコーティングし、1錠あたり124mgのフィルムコーティング錠を得た。Example 26
Using a tablet coating machine (DRC-200, manufactured by Powrex), a coating agent (OPADRY 00F440000, Nippon Colorcon G.K .: Hypromellose 2910 71.500%, Macrogol 6000 14.166%, talc 7.167%, titanium oxide 7.067% and iron sesquioxide 0.100% dispersed in water) were coated at a ratio of 4 mg per tablet to obtain 124 mg of a film-coated tablet per tablet.
実施例２７
実施例６の素錠に、実施例２６と同様にコーティングし、1錠あたり124mgのフィルムコーティング錠を得た。Example 27
The uncoated tablet of Example 6 was coated in the same manner as in Example 26 to obtain 124 mg of a film-coated tablet per tablet.
実施例２８
実施例７の素錠に、実施例２６と同様にコーティングし、1錠あたり124mgのフィルムコーティング錠を得た。Example 28
The uncoated tablet of Example 7 was coated in the same manner as in Example 26 to obtain 124 mg of a film-coated tablet per tablet.
実施例２９
実施例１の素錠に、実施例２６と同様にコーティングし、1錠あたり124mgのフィルムコーティング錠を得た。Example 29
The uncoated tablet of Example 1 was coated in the same manner as in Example 26 to obtain 124 mg of a film-coated tablet per tablet.
実施例３０
実施例１３の素錠に、実施例２６と同様にコーティングし、1錠あたり124mgのフィルムコーティング錠を得た。Example 30
The uncoated tablet of Example 13 was coated in the same manner as in Example 26 to obtain 124 mg of a film-coated tablet per tablet.
比較例１
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール33.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ヒドロキシプロピルセルロース水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Comparative Example 1
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 33.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed and measured. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 1% aqueous solution of hydroxypropylcellulose was sprayed and granulated, and dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
比較例２
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール33.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％ヒドロキシプロピルメチルセルロース水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Comparative Example 2
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 33.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed and measured. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 1% aqueous solution of hydroxypropylmethylcellulose was sprayed and granulated, and dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
比較例３
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール33.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、1％α化デンプン水溶液200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Comparative Example 3
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 33.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed and measured. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of a 1% pregelatinized starch aqueous solution was sprayed and granulated, and dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
比較例４
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール25.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0ｇおよびスクラロース1.0gを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、5%ポリビニルアルコール（部分けん化物）水溶液200gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5%相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Comparative Example 4
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 25.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200 g of a 5% polyvinyl alcohol (partially saponified) aqueous solution was sprayed to granulate, dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% based on the mass of the plain tablet is added through a sieve having an opening of 500 μm, and magnesium stearate equivalent to 2.5% based on the mass of the uncoated tablet has a sieve having an opening of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
比較例５
トスフロキサシントシル酸塩水和物100.0g、Ｌ−アスパラギン酸30.0g、エリスリトール35.0g、軽質無水ケイ酸8.0g、低置換度ヒドロキシプロピルセルロース12.0g、クロスポビドン8.0gおよびスクラロース1.0ｇを秤取し、目開き500μmの篩で篩過後、転動流動造粒乾燥機に仕込み、混合した。その後、水200.0gを噴霧して造粒し、乾燥および整粒して造粒末を得た。この造粒末に素錠質量に対して0.5％相当量の軽質無水ケイ酸を目開き500μmの篩を通して加え、また素錠質量に対して2.5％相当量のステアリン酸マグネシウムを目開き180μmの篩を通して加え、混合し打錠末を得た。この打錠末を、錠剤径6.5mmで碁石面の杵を用い、打錠機で圧縮成型し、1錠あたり120mgの割線および刻印を有する円形の素錠を得た。Comparative Example 5
100.0 g of tosfloxacin tosylate hydrate, 30.0 g of L-aspartic acid, 35.0 g of erythritol, 8.0 g of light anhydrous silicic acid, 12.0 g of low-substituted hydroxypropylcellulose, 8.0 g of crospovidone and 1.0 g of sucralose were weighed. After sieving through a sieve having an opening of 500 μm, the mixture was charged into a tumbling fluidized-bed granulator and mixed. Thereafter, 200.0 g of water was sprayed to granulate, dried and sized to obtain a granulated powder. To the granulated powder, light anhydrous silicic acid equivalent to 0.5% with respect to the mass of the uncoated tablet is added through a sieve with an opening of 500 μm, and magnesium stearate equivalent to 2.5% with respect to the mass of the uncoated tablet with a mesh of 180 μm. And mixed to obtain a tableting powder. This tableting powder was compression-molded with a tableting machine using a punch having a tablet diameter of 6.5 mm and a go stone surface to obtain a round plain tablet having a score of 120 mg per tablet and a stamp.
本発明の錠剤は、小児等の服薬コンプライアンスを向上した小児用の抗菌剤として有用である。 INDUSTRIAL APPLICABILITY The tablet of the present invention is useful as an antibacterial agent for children with improved compliance with children and the like.
Claims (8)
結合剤が、水溶性ポリビニル系高分子、アルカリ処理ゼラチンおよび酸処理ゼラチンから選ばれる一種または二種以上であり、結合剤の含有率が、錠剤質量に対して５％未満である、錠剤。 A tablet comprising (1) tosfloxacin tosylate, (2) a binder, and (3) an acidic amino acid;
Tablets wherein the binder is one or more selected from a water-soluble polyvinyl polymer , alkali-treated gelatin and acid-treated gelatin , and the content of the binder is less than 5% based on the tablet mass.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016088740 | 2016-04-27 | ||
| JP2016088740 | 2016-04-27 | ||
| PCT/JP2017/016681 WO2017188361A1 (en) | 2016-04-27 | 2017-04-27 | Tablet containing tosufloxacin tosilate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2017188361A1 JPWO2017188361A1 (en) | 2019-02-28 |
| JP6647395B2 true JP6647395B2 (en) | 2020-02-14 |
Family
ID=60160841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018514690A Active JP6647395B2 (en) | 2016-04-27 | 2017-04-27 | Tablets containing tosfloxacin tosylate |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6647395B2 (en) |
| TW (1) | TWI749007B (en) |
| WO (1) | WO2017188361A1 (en) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6272616A (en) * | 1985-09-27 | 1987-04-03 | Toyama Chem Co Ltd | Antibacterial agent |
| DE10351448A1 (en) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Flavor-containing drug formulations with improved pharmaceutical properties |
| JP5202856B2 (en) * | 2006-03-06 | 2013-06-05 | 富山化学工業株式会社 | Granular solid formulation containing tosfloxacin tosylate |
| JP5318400B2 (en) * | 2006-11-20 | 2013-10-16 | 第一三共株式会社 | Tablets containing levofloxacin |
| JP2009089982A (en) * | 2007-10-11 | 2009-04-30 | Ohara Yakuhin Kogyo Kk | Method of granular material for making tablets |
| JP2009269874A (en) * | 2008-05-09 | 2009-11-19 | Daido Kasei Kogyo Kk | Aqueous liquid preparation |
| JP2010013402A (en) * | 2008-07-04 | 2010-01-21 | Nof Corp | Coating and granulating agent for tableting |
| JP2011026312A (en) * | 2009-06-30 | 2011-02-10 | Kowa Co | Solid formulation containing aspartic acid or salt thereof |
| JP6245677B2 (en) * | 2012-01-20 | 2017-12-13 | ニプロ株式会社 | Orally disintegrating tablets |
| JP5799061B2 (en) * | 2013-08-23 | 2015-10-21 | 富山化学工業株式会社 | Granular solid formulation containing tosufloxacin and polyvinylpyrrolidone |
| CN106176646B (en) * | 2016-08-19 | 2020-08-11 | 珠海同源药业有限公司 | Tosufloxacin tosylate dispersible tablets and preparation method thereof |
-
2017
- 2017-04-27 TW TW106114037A patent/TWI749007B/en active
- 2017-04-27 WO PCT/JP2017/016681 patent/WO2017188361A1/en active Application Filing
- 2017-04-27 JP JP2018514690A patent/JP6647395B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2017188361A1 (en) | 2019-02-28 |
| WO2017188361A1 (en) | 2017-11-02 |
| TW201740941A (en) | 2017-12-01 |
| TWI749007B (en) | 2021-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7028829B2 (en) | Orally disintegrating tablet and its manufacturing method | |
| JP5583659B2 (en) | 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide-containing tablets and granulated powder | |
| JP2023063386A (en) | Orally administered formulation masking bitterness of silodosin | |
| JPWO2002024166A1 (en) | Oral formulation with good disintegration | |
| JPWO2005055989A1 (en) | Drug-containing particles and solid preparation containing the particles | |
| WO2015122477A1 (en) | Orally disintegrating tablet coated with film | |
| WO2016051782A1 (en) | Oral preparation in which bitter taste of bitter-tasting drug is masked | |
| JP6647395B2 (en) | Tablets containing tosfloxacin tosylate | |
| RU2633477C2 (en) | Pill containing methanesulfonate hydrate of 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2,3-dihydro-1h-isoindole-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | |
| JP6112696B1 (en) | Tablets containing solithromycin | |
| JP6538321B2 (en) | Oral composition | |
| JP7079209B2 (en) | Pharmaceutical composition and its manufacturing method | |
| JP2005139086A (en) | Quick-disintegration preparation | |
| JP6600084B2 (en) | Tablets containing tosufloxacin tosylate, disintegrant and acidic amino acid | |
| JP2019199463A (en) | Orally disintegrating tablets containing sugar or sugar alcohol granule modified with ethyl cellulose | |
| JP7288625B2 (en) | Orally disintegrating tablet containing silodosin | |
| JP7133811B2 (en) | tablet | |
| JP7023186B2 (en) | Orally disintegrating tablets containing dementia treatment | |
| JP6427634B1 (en) | An oral solid preparation containing silodosin excellent in light stability | |
| JP6160813B2 (en) | High content levofloxacin tablets | |
| JP6150564B2 (en) | Orally rapidly disintegrating tablets | |
| JP2021024843A (en) | Solid preparation containing iguratimod | |
| JP2007284394A (en) | Coated solid preparation | |
| JP2011213606A (en) | Method for producing solid preparation containing donepezil | |
| JP2010241695A (en) | Intraoral quickly disintegrating tablet and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181026 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20181026 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191001 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191120 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200114 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6647395 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |